The Bill & Melinda Gates Foundation, through its Strategic Investment Fund (SIF), focuses its investments on driving positive social impact globally, particularly in areas such as global health, agriculture, financial services, and education for low-income populations. Their strategy is "impact first, financial sustainability second," utilizing flexible financial instruments like equity, debt, and grants to support game-changing developments and scale breakthrough business models and technology innovations.
62% of their portfolio is in Biotech & Life Sciences. They made 6 investments in the last 12 months. Their most common stage is series-a (50% of deals). Average disclosed round size is $89.2M (across 6 rounds with reported amounts).
Portfolio
8
Fund Size
$77.2B
Top Stage
Series A
Last 12 Mo
6
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| PPlasmaLeap Technologies | Series A | $20M | Mar 2026 |
 Ten63 Therapeutics | Unknown | — | Feb 2026 |
 Addition Therapeutics | Unknown | $100M | Dec 2025 |
 Nilo Therapeutics | Series A | $101M | Oct 2025 |
 Puna Bio | Series A | — | Jul 2025 |
 Lumen Bioscience | Series C | $30M | Jul 2025 |
| BButterfly Network | Growth | $250M | Sep 2018 |
| PPHASE Scientific | Series A | $34M | — |
Top Co-Investors
Last updated: 16 April 2026